Lee Ellis

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer
    W Liu
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Br J Cancer 90:1620-6. 2004
  2. pmc Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells
    M Akagi
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Br J Cancer 88:796-802. 2003
  3. pmc Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells
    S Samuel
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Oncogene 30:1205-12. 2011
  4. pmc Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells
    J S Wey
    Department of Surgical Oncology, Unit 444, The University of Texas, MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Br J Cancer 93:233-41. 2005
  5. pmc ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer
    M F McCarty
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030 4009, USA
    Br J Cancer 90:705-11. 2004
  6. pmc Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis
    O Stoeltzing
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 87:1182-7. 2002
  7. pmc Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinal cancer cell lines
    Shaija Samuel
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23208. 2011
  8. pmc Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells
    D Bose
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Br J Cancer 105:1759-67. 2011
  9. pmc Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells
    Fan Fan
    Department of Cancer Biology, University of Texas MD Anderson Cancer Center Houston, Texas, USA
    Cancer Med 1:5-16. 2012
  10. pmc Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration
    F Fan
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Unit 173, PO Box 301402, Houston, TX 77030 1402, USA
    Br J Cancer 104:1270-7. 2011

Detail Information

Publications94

  1. pmc Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer
    W Liu
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Br J Cancer 90:1620-6. 2004
    ..We conclude that overexpression of ephrin-B2 suppresses tumour cell growth and vascular function in this in vivo colon cancer model...
  2. pmc Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells
    M Akagi
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Br J Cancer 88:796-802. 2003
    ..Activation of EGF-R might contribute to gastric cancer angiogenesis by a mechanism that involves upregulation of VEGF and NRP-1 expression via multiple signalling pathways...
  3. pmc Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells
    S Samuel
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Oncogene 30:1205-12. 2011
    ..Our findings suggest a novel and distinct function of VEGF in mediating autocrine/intracrine CRC cell survival...
  4. pmc Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells
    J S Wey
    Department of Surgical Oncology, Unit 444, The University of Texas, MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Br J Cancer 93:233-41. 2005
    ..Targeting NRP-1 in pancreatic cancer cells may downregulate survival signalling pathways and increase sensitivity to chemotherapy...
  5. pmc ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer
    M F McCarty
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030 4009, USA
    Br J Cancer 90:705-11. 2004
    ..These data suggest that ZD6126 may be worthy of investigation in the treatment of primary gastric adenocarcinoma...
  6. pmc Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis
    O Stoeltzing
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 87:1182-7. 2002
    ..05). Our results suggest that angiopoietin-1 is an important mediator of angiogenesis and vascular permeability and thus could theoretically serve as an anti-neoplastic agent for patients with carcinomatosis from colorectal cancer...
  7. pmc Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinal cancer cell lines
    Shaija Samuel
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23208. 2011
    ..01). Collectively, our results demonstrate that tumor cell-derived NRP-2 mediates critical survival signaling in gastrointestinal cancer cells...
  8. pmc Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells
    D Bose
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Br J Cancer 105:1759-67. 2011
    ..We hypothesised that chemoresistant colorectal cancer (CRC) cells generate soluble factors that enhance survival of chemonaive tumour cells...
  9. pmc Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells
    Fan Fan
    Department of Cancer Biology, University of Texas MD Anderson Cancer Center Houston, Texas, USA
    Cancer Med 1:5-16. 2012
    ..Increased Snail expression induces EMT and the CSC-like phenotype in CRC cells, which enhance cancer cell invasion and chemoresistance. Thus, Snail is a potential therapeutic target in metastatic CRC...
  10. pmc Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration
    F Fan
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Unit 173, PO Box 301402, Houston, TX 77030 1402, USA
    Br J Cancer 104:1270-7. 2011
    ..This study was carried out to determine the molecular and phenotypic changes in CRC cells after chronic Bev exposure in vitro...
  11. doi VEGF-targeted therapy: mechanisms of anti-tumour activity
    Lee M Ellis
    Department of Surgical Oncology, Unit 444, University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, Texas 77230 1402, USA
    Nat Rev Cancer 8:579-91. 2008
    ..A better understanding of these mechanisms will lead to future advances in the use of these agents in the clinic...
  12. ncbi Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer
    Lee M Ellis
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Semin Oncol 33:S1-7. 2006
    ..However, bevacizumab has been shown to increase the response rates with chemotherapy in almost all tumor types studied in phase III trials...
  13. ncbi The role of neuropilins in cancer
    Lee M Ellis
    University of Texas M D Anderson Cancer Center, Unit 444, P O Box 301402, Houston, TX 77230 1402, USA
    Mol Cancer Ther 5:1099-107. 2006
    ..The therapeutic implications of these data are far-reaching and suggest that neuropilin-targeted interventions may be useful as a component of antineoplastic therapy...
  14. ncbi Bevacizumab
    Lee M Ellis
    University of Texas MD Anderson Cancer Center, Houston 77230 1402, USA
    Nat Rev Drug Discov . 2005
    ..It is the first approved agent to target tumour angiogenesis...
  15. ncbi Antiangiogenic therapy at a crossroads: clinical trial results and future directions
    Lee M Ellis
    Department of Surgery, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030 4009, USA
    J Clin Oncol 21:281s-283s. 2003
  16. ncbi Preclinical data targeting vascular endothelial growth factor in colorectal cancer
    Lee M Ellis
    Department of Surgical Oncology, Box 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Clin Colorectal Cancer 4:S55-61. 2004
    ..Understanding the mechanisms of the role of VEGF in CRC angiogenesis and the effect of anti-VEGF therapy on the tumor vasculature will allow oncologists to optimize therapeutic regimens targeting VEGF and its receptors...
  17. ncbi Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
    Lee M Ellis
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Clin Cancer Res 14:6371-5. 2008
    ....
  18. ncbi Role of angiogenesis inhibitors in cancer treatment
    L M Ellis
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 15:39-46. 2001
    ..Understanding the basic principles that drive tumor angiogenesis will lead to the development of therapies that will likely prolong survival without the toxicity associated with standard chemotherapy...
  19. ncbi Angiopoietins and their role in colon cancer angiogenesis
    Lee M Ellis
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:31-5. 2002
    ..This may ultimately lead to tumor dormancy by transforming a rapidly growing tumor into an indolent tumor...
  20. ncbi Synopsis of angiogenesis inhibitors in oncology
    Lee M Ellis
    Department of Surgical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:14-22. 2002
    ..Nevertheless, the understanding of the basic principles that drive tumor angiogenesis will lead to the development of therapies that will likely prolong survival without the toxicity associated with standard chemotherapy...
  21. ncbi Antiangiogenic therapy targeting factors that enhance endothelial cell survival
    Wenbiao Liu
    Departments of Cancer Biology and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Oncol 29:96-103. 2002
    ..Lastly, pericytes contribute to EC stabilization by cell-cell contact and/or secretion of survival factors, such as vascular endothelial growth factor. Targeting EC survival factors may provide a novel antineoplastic strategy for cancer...
  22. ncbi Outcome after curative resection for locally recurrent rectal cancer
    Isabelle Bedrosian
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, Texas 77030, USA
    Dis Colon Rectum 49:175-82. 2006
    ..We sought to determine the influence of clinical, pathologic, and biologic (p53, bcl-2, and ki-67) variables on survival after curative resection of locally recurrent rectal cancer...
  23. pmc Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
    Eddie K Abdalla
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg 239:818-25; discussion 825-7. 2004
    ..To examine recurrence and survival rates for patients treated with hepatic resection only, radiofrequency ablation (RFA) plus resection or RFA only for colorectal liver metastases...
  24. ncbi Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells
    Maribelis Ruiz
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 64:631-8. 2004
    ..AP-2 acts as a tumor-suppressor gene in prostate cancer. Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer...
  25. ncbi Advances in the treatment of liver tumors
    Steven A Curley
    The University of Texas M D Anderson Cancer Center, Houston, USA
    Curr Probl Surg 39:449-571. 2002
  26. ncbi Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy
    Alexander A Parikh
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Gastrointest Surg 7:1082-8. 2003
    ..It may therefore provide a better therapeutic option, particularly in patients with multiple colorectal metastases...
  27. doi Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  28. ncbi Phase I study of recombinant human endostatin in patients with advanced solid tumors
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3792-803. 2002
    ..We evaluated recombinant human endostatin (rh-Endo) in a phase I trial designed to assess safety, pharmacokinetics, and serum markers of angiogenesis in patients with solid tumors...
  29. ncbi Vascular endothelial growth factor receptors: expression and function in solid tumors
    Jane S Wey
    Department of Surgical Oncology, Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 2:37-45. 2004
    ..This elucidation of VEGF activity may further refine antineoplastic regimens for solid malignancies...
  30. doi Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases
    Susan B Kesmodel
    Department of Surgical Oncology, Cancer Biology, Biostatistics, and Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5254-60. 2008
    ..We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases...
  31. ncbi Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma
    Yehuda Z Patt
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:578-86. 2004
    ..The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma...
  32. ncbi Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care
    Debashish Bose
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Lancet Oncol 11:373-82. 2010
    ....
  33. ncbi Increased apoptosis in metastatic human colonic adenocarcinomas
    Paula M Termuhlen
    Departments of Cancer Biology, Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Biol Ther 1:58-63. 2002
    ..Our data demonstrate that the molecular events associated with acquisition of the metastatic phenotype sensitize colon cancer cells to some pro-apoptotic stimuli...
  34. ncbi Debunking dogma: surgery for four or more colorectal liver metastases is justified
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Gastrointest Surg 10:240-8. 2006
    ..Certain clinicopathologic factors, including lack of response to neoadjuvant chemotherapy, were associated with a worse prognosis...
  35. ncbi The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression
    Lin Yang
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:4321-30. 2008
    ..Thus, the hitherto uncharacterized ZKSCAN3 adds to an expanding set of encoded products contributing to the progression of colorectal cancer...
  36. ncbi Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells
    Maryam R Sartippour
    Department of Surgery, Division of Oncology and Center for Human Nutrition, University of California, Los Angeles 90095, USA
    J Nutr 132:2307-11. 2002
    ..Inhibition of VEGF transcription appeared to be one of the molecular mechanism(s) involved in the antiangiogenic effects of green tea, which may contribute to its potential use for breast cancer treatment and/or prevention...
  37. ncbi Angiogenesis and its role in colorectal tumor and metastasis formation
    Lee M Ellis
    Departments of Surgical Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030, USA
    Semin Oncol 31:3-9. 2004
    ..This article will highlight what is known about colorectal cancer angiogenesis, and will discuss how therapy targeting VEGF may enhance the effects of chemotherapy (and radiation therapy)...
  38. ncbi Promises and pitfalls of anti-angiogenic therapy in clinical trials
    Marya F McCarty
    Dept of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, P O Box 444, Houston, TX 77030, USA
    Trends Mol Med 9:53-8. 2003
    ..Further insights into the complex process of angiogenesis are essential for the development of effective anti-angiogenic regimens...
  39. ncbi Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors
    Oliver Stoeltzing
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 63:3370-7. 2003
    ..Thus, Ang-1 could potentially serve as an antineoplastic or anti-permeability agent for patients with metastatic colorectal cancer...
  40. ncbi Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice
    Christiane J Bruns
    Departments of Cancer Biology and Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Cancer 102:101-8. 2002
    ..Anti-VEGF receptor-2 therapy in combination with gemcitabine may be a novel therapeutic approach for advanced pancreatic cancer...
  41. ncbi Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma
    Yehuda Z Patt
    Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 21:421-7. 2003
    ....
  42. ncbi Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis
    Lianglin Zhang
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:2034-42. 2002
    ..Collectively, our data suggested that anti-VEGF receptor 2 in combination with continuous low-dose doxorubicin may provide a new therapeutic approach for human soft tissue sarcoma in the clinic...
  43. ncbi Biology of angiogenesis in tumors of the gastrointestinal tract
    Niels Reinmuth
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Microsc Res Tech 60:199-207. 2003
    ..A thorough understanding of the role these factors play in the angiogenic process may lead to the development of novel therapeutic antineoplastic strategies...
  44. ncbi Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis
    Oliver Stoeltzing
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:722-33. 2003
    ..This review focuses on angiogenesis in colorectal cancer metastasis formation as a target for antiangiogenic therapy, describing the experience from experimental studies and current clinical trials...
  45. ncbi Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer
    Courtney L Scaife
    Departments of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:348-54. 2003
    ..We conducted a study to determine the feasibility of using HAI after RFA for colorectal cancer (CRC) liver metastases...
  46. ncbi Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice
    Niels Reinmuth
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 63:2079-87. 2003
    ..The use of agents such as integrin antagonists that target multiple cell types involved in angiogenesis may be a more effective method of inhibiting angiogenesis than agents targeting only the endothelial cells...
  47. ncbi Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice
    Todd W Bauer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ann Surg Oncol 14:2838-46. 2007
    ..Colorectal carcinomas (CRC) express high levels of insulin-like growth factor-I/II (IGF-I/II) and the receptor (IGF-IR). We hypothesized that selective inhibition of IGF-IR would inhibit hepatic growth of human CRC in mice...
  48. ncbi Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer
    Niels Reinmuth
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Lab Invest 82:1377-89. 2002
    ..These studies demonstrate that the IGF-IR plays an important role in multiple mechanisms that mediate the growth, angiogenesis, and metastasis of human colon cancer. IGF-IR is a valid target for the therapy of human colon cancer...
  49. ncbi Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation
    Nestor F Esnaola
    Department of Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Gastrointest Surg 6:224-32; discussion 232. 2002
    ..3; 95% CI, 2.0 to 19.9). Tumor size and grade are strong predictors of microvascular invasion. A tumor biopsy with pathologic grading at the time of pretransplantation ablative therapy could improve selection of patients with HCC for OLT...
  50. ncbi Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer
    Niels Reinmuth
    Departments of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3259-69. 2002
    ..To elucidate the in vitro and in vivo effects of IGF-IR in human colon cancer growth and angiogenesis, HT29 cells were transfected with a truncated dominant-negative (DN) form of IGF-IR or vector alone...
  51. doi Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis
    Puja Gaur
    Departments of Surgical Oncology and Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:6763-70. 2009
    ..Herein, we briefly review (a) the role of SEMA3s in mediating tumor growth, (b) the SEMA3 receptors neuropilins and plexins, and (c) the potential competition between SEMA3s and VEGF family members for neuropilin binding...
  52. pmc Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis
    Alexander A Parikh
    Departments of Surgical Oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Pathol 164:2139-51. 2004
    ..This study also suggests that EGF and mitogen-activated protein kinase signaling pathways play an important role in NRP-1 regulation in colon cancer cells...
  53. pmc Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies
    Jeffry Cutrera
    The University of Texas MD Anderson Cancer Center, Department of Pediatrics, 1515 Holcombe Blvd, Houston, TX 77030, United States
    Cancer Lett 329:68-73. 2013
    ..This discovery provides an effective approach to generate spontaneous-like metastatic tumor models which will satisfy the urgent need for studying metastasis biology and discovering novel therapeutics...
  54. ncbi Clinical and in vitro studies of imatinib in advanced carcinoid tumors
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:234-40. 2007
    ..Effective systemic therapy options for carcinoid tumors are lacking. We conducted in vitro studies and a phase II clinical trial to explore the activity of imatinib in carcinoid tumors...
  55. ncbi Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines
    Anthony D Yang
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Clin Cancer Res 12:4147-53. 2006
    ..In preliminary studies, we observed that oxaliplatin-resistant (OxR) colorectal cancer (CRC) cells underwent morphologic changes suggestive of a migratory phenotype, leading us to hypothesize that OxR CRC cells undergo EMT...
  56. ncbi Simplified staging for hepatocellular carcinoma
    Jean Nicolas Vauthey
    International Cooperative Study Group on Hepatocellular Carcinoma, Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 20:1527-36. 2002
    ..The current American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC) fails to stratify patients adequately with respect to prognosis...
  57. ncbi Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    Dario Ribero
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2761-7. 2007
    ..The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology...
  58. ncbi Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells
    Nikolaos A Dallas
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Cancer Metastasis Rev 26:433-41. 2007
    ..Elucidating the function of VEGF receptors on tumor cells should help us to better understand the potential mechanisms of action of anti-VEGF therapies...
  59. doi Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:824-30. 2010
    ..We designed this Phase II trial to assess the efficacy and safety of the addition of bevacizumab to concurrent neoadjuvant capecitabine-based chemoradiation in locally advanced rectal cancer...
  60. pmc Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 123:1883-91. 2008
    ..Controlling for smoking exposure might be a prudent approach to the prevention of HCC, especially in patients with chronic viral hepatitis infections...
  61. pmc Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    Scott Kopetz
    University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
    J Clin Oncol 28:453-9. 2010
    ....
  62. ncbi Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:517-24. 2003
    ..This article investigates the relationship between objective tumor response and sphincter preservation in low rectal carcinoma patients...
  63. pmc Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress
    Scott Kopetz
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center and Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas 77030 4009, USA
    Cancer Res 69:3842-9. 2009
    ..These results suggest that Src inhibitors combined with oxaliplatin may have efficacy in metastatic colon cancer and may provide the first indication of a molecular phenotype that might be susceptible to such combinations...
  64. doi Targeting tumor angiogenesis
    Puja Gaur
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Oncol 36:S12-9. 2009
    ....
  65. ncbi Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Arch Surg 141:537-43; discussion 543-4. 2006
    ..A subset of patients with sarcoma liver metastasis may benefit from hepatic resection and/or ablation...
  66. ncbi Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 29:219-24. 2006
    ..To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer...
  67. ncbi Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis
    Chandrajit P Raut
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas, 77030 4009, USA
    Ann Surg Oncol 12:616-28. 2005
    ..We prospectively evaluated survival rates in patients with early-stage, unresectable HCC treated with RFA...
  68. ncbi HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
    Michael J Gray
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Boulevard, Houston, TX 77030, USA
    Oncogene 24:3110-20. 2005
    ..These data suggest that the binding of both STAT3 and HIF-1alpha to the VEGF promoter is required for maximum transcription of VEGF mRNA following hypoxia...
  69. ncbi Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma
    Alexander A Parikh
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:720-9. 2003
    ....
  70. pmc Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer
    Oliver Stoeltzing
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Am J Pathol 163:1001-11. 2003
    ..02). Our results suggest that autocrine activation of the IGF-IR system significantly affects VEGF expression and angiogenesis in human pancreatic cancer. Thus, IGF-IR may be a valid target in the treatment of pancreatic cancer...
  71. ncbi Epidermal growth factor receptor in tumor angiogenesis
    Lee M Ellis
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030 4009, USA
    Hematol Oncol Clin North Am 18:1007-21, viii. 2004
    ..This article focuses on the preclinical evidence for activation of the epidermal growth factor receptor (EGFR) in promoting angiogenesis and the efficacy of anti-EGFR agents in inhibiting angiogenesis and tumor growth...
  72. pmc Is extended hepatectomy for hepatobiliary malignancy justified?
    Jean Nicolas Vauthey
    Departments of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    Ann Surg 239:722-30; discussion 730-2. 2004
    ..Extended hepatectomy may be required to provide the best chance for cure of hepatobiliary malignancies. However, the procedure may be associated with significant morbidity and mortality...
  73. ncbi ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer
    Marya F McCarty
    Department of Surgical Oncology, Unit 444, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 3:1041-8. 2004
    ..In conclusion, therapies such as ZD6474 that target two distinct aspects of tumor growth, angiogenesis and tumor cell proliferation, warrant further investigation...
  74. ncbi Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?
    Paulo M Hoff
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Oncology (Williston Park) 18:736-41; discussion 742, 745-6. 2004
    ....
  75. ncbi Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab
    Lee M Ellis
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:4853-5. 2005
  76. ncbi Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer
    E Ramsay Camp
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 12:2628-33. 2006
    ..Because these molecules regulate one another's expression, we hypothesized that NO synthase (NOS) inhibition produces effects comparable to those of anti-VEGF therapy on human pancreatic cancer xenografts...
  77. ncbi Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1145-51. 2006
    ..To study the safety of bevacizumab with capecitabine-based chemoradiotherapy...
  78. pmc Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Ann Surg 239:450-8. 2004
    ..We performed this prospective analysis to determine early (within 30 days) and late (more than 30 days after) complication rates associated with hepatic tumor RFA...
  79. ncbi Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3804-14. 2002
    ..We present the initial results of a dose-finding clinical trial of recombinant human endostatin (rh-Endo) that examined potential surrogates for response to antiangiogenic therapy...
  80. pmc Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
    Matthew H Kulke
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 29:934-43. 2011
    ....
  81. ncbi Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy
    Atin Agarwal
    Department of Pathology, Baylor College of Medicine, Houston, Texas
    Cancer 119:4231-41. 2013
    ..The current study was conducted to determine whether quantified pathologic response assessed as a percentage of residual tumor cells is predictive of recurrence-free survival (RFS) in patients with rectal cancer...
  82. ncbi Desmoid tumor of the small bowel and the mesentery
    Silvana C Faria
    Division of Diagnostic Imaging, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 57, Houston, TX 77030, USA
    AJR Am J Roentgenol 183:118. 2004
  83. ncbi Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma
    Isabelle Bedrosian
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Gastrointest Surg 8:56-62; discussion 62-3. 2004
    ..Despite a substantial reduction in tumor volume with neoadjuvant CRT, local excision should be recommended with caution in patients with locally advanced rectal cancer...
  84. ncbi Antiangiogenic therapy: more promise and, yet again, more questions
    Lee M Ellis
    J Clin Oncol 21:3897-9. 2003
  85. ncbi Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice
    Oliver Stoeltzing
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Int J Cancer 104:496-503. 2003
    ..The enhancement of antineoplastic activity from the combination of anti-angiogenic therapy and chemotherapy may be a promising approach for treating metastatic colorectal cancer...
  86. ncbi Current overview of angiogenesis inhibitors
    Lee M Ellis
    Surgical Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, TX, USA
    Clin Adv Hematol Oncol 2:494-6, 520. 2004
  87. ncbi Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
    Sven A Lang
    Department of Surgery, University of Regensburg, Medical Center, Regensburg, Germany
    Int J Cancer 120:1803-10. 2007
    ..In conclusion, mTOR is frequently activated in human gastric cancer and represents a promising new molecular target for therapy...
  88. ncbi Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies
    Lee M Ellis
    John Wayne Cancer Institute, Santa Monica, CA, USA
    Clin Adv Hematol Oncol 4:suppl 1-10; quz 11-2. 2006
    ..These other issues, including the biologic rationale for anti-VEGF therapy, as well as recent clinical trial data with anti-VEGF agents in colorectal, pancreatic, lung, kidney, and brease cancers, are discussed...
  89. ncbi Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
    Fairooz F Kabbinavar
    Division of Hematology Oncology, Department of Medicine, 10945 Le Conte Ave, University of California Los Angeles 2338 John, PVUB MC, 718707, Los Angeles, CA 90095 7187, USA
    Clin Colorectal Cancer 4:S69-73. 2004
    ..The current study indicates that subpopulations of patients with advanced age or poor performance status could be treated successfully with 5-FU/LV in combination with bevacizumab without excessive toxicities...
  90. ncbi Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Daniel J Hicklin
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014, USA
    J Clin Oncol 23:1011-27. 2005
    ....
  91. ncbi The vascular endothelial growth factor family and its receptors
    Alexander A Parikh
    Department of Surgery Surgical Oncology, Temple University School of Medicine, Fourth Floor, Parkinson Pavilion, 3401 North Broad Street, Philadelphia, PA 19140, USA
    Hematol Oncol Clin North Am 18:951-71, vii. 2004
    ..A thorough understanding of the VEGF system is paramount in optimizing antiangiogenic therapies as a component of antineoplastic regimens...
  92. ncbi A targeted approach for antiangiogenic therapy of metastatic human colon cancer
    Lee M Ellis
    Department of Cancer Biology and Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, 444 Houston, Texas 77030 4009, USA
    Am Surg 69:3-10. 2003
    ..These angiogenic mediators thus serve as targets for therapy of metastatic colon cancer and have shown promise in preclinical trials...
  93. doi Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies
    Axel Grothey
    Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota, USA
    Cancer J 14:170-7. 2008
    ....
  94. ncbi The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion
    Yutaka Takahashi
    Department of Surgical Oncology, Cancer Research Institute, Kanazawa University, Japan
    Oncol Rep 10:9-13. 2003
    ..These results suggest that angiogenic switch may occur between Tis and T1, i.e. simultaneous to initiation of invasion, in the early development of colon cancer...

Research Grants11

  1. TRAINING OF ACADEMIC SURGICAL ONCOLOGISTS
    Lee Ellis; Fiscal Year: 2007
    ..As a result, this is a highly stimulating environment in which aspiring academic surgical oncologists can receive research training under the aegis of the T32 program. ..
  2. Function of VEGF Receptor-1 on Colorectal Cancer Cells
    Lee Ellis; Fiscal Year: 2007
    ..In addition, it is possible that VEGFR-1 expression on CRC cells may serve as a "predictive factor" for anti-VEGF/receptor containing anti-neoplastic regimens. ..
  3. Function of VEGF Receptor-1 on Colorectal Cancer Cells
    Lee Ellis; Fiscal Year: 2006
    ..In addition, it is possible that VEGFR-1 expression on CRC cells may serve as a "predictive factor" for anti-VEGF/receptor containing anti-neoplastic regimens. ..
  4. Function of VEGF Receptor-1 on Colorectal Cancer Cells
    Lee Ellis; Fiscal Year: 2009
    ..In addition, it is possible that VEGFR-1 expression on CRC cells may serve as a "predictive factor" for anti-VEGF/receptor containing anti-neoplastic regimens. ..